Obesity, growth hormone and weight loss

Molecular and Cellular Endocrinology

Volumn 316, Issue 2, 2010, Pages 147-153

  Rasmussen, Michael Højby ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Growth hormone; Insulin like growth factor; Obesity; Weight loss

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE BINDING PROTEIN; GROWTH HORMONE RECEPTOR; HUMAN GROWTH HORMONE[176-191][176 TYROSINE]; PLACEBO; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C;

ABDOMINAL OBESITY; BODY COMPOSITION; BODY FAT DISTRIBUTION; BODY WEIGHT; CALORIC RESTRICTION; CLINICAL TRIAL; DOSE RESPONSE; DRUG MEGADOSE; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HORMONAL REGULATION; HORMONE ACTION; HORMONE BINDING; HORMONE SUBSTITUTION; HUMAN; INTRAABDOMINAL FAT; LIPID STORAGE; LOW DRUG DOSE; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; WEIGHT REDUCTION;

BODY COMPOSITION; CALORIC RESTRICTION; CARDIOVASCULAR DISEASES; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LIPID METABOLISM; OBESITY; RISK FACTORS; SIGNAL TRANSDUCTION; WEIGHT LOSS;

EID: 72449124122     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2009.08.017     Document Type: Review

References (102)

1. Albert S.G., and Mooradian A.D. Low-dose recombinant human growth hormone as adjuvant therapy to lifestyle modifications in the management of obesity. J. Clin. Endocrinol. Metab. 89 (2004) 695-701
2. Ahn C.W., Kim C.S., Nam J.H., et al. Effects of growth hormone on insulin resistance and atherosclerotic risk factors in obese type 2 diabetic patients with poor glycaemic control. Clin. Endocrinol. 64 (2006) 444-449
3. Ardizzi A., Grugni G., Guzzaloni G., Moro D., and Morabito F. Effects of protracted rhGH administration on body composition and intermediate metabolism in juvenile obesity. Acta. Med. Auxol. 28 (1996) 103-109
4. Attallah H.Y., Friedlander A.L., Nini-Murcia M., Hoffmann A.R. Effects of Growth hormone and pioglitazone in viscerally obese adults with impaired glucose tolerance: a factorial clinical trial. PLoS Clin. Trials 2007; 2(5):e21. doi:10.1371/journal.pctr.0020021.
5. Bengtsson B.A., Eden S., Lonn L., Kvist H., Stokland A., Lindstedt G., Bosaeus I., Tolli J., Sjostrom L., and Isaksson O.G. Treatment of adults with growth hormone deficiency with recombinant human GH. J. Clin. Endocrinol. Metab. 76 (1993) 309-317
6. Beshyah S.A., Henderson A., Niththyanathan R., Sharp P., Richmond W., and Johnston D. Metabolic abnormalities in growth hormone-deficient adults. II. Carbohydrate tolerance and lipid metabolism. Endocrinol. Metab. 1 (1994) 173-180
7. Binnerts A., Swart G.R., Wilson J.H.P., et al. The effect of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis, as well as body composition. Clin. Endocrinol. 37 (1992) 79-87
8. Blackman M.R., Sorkin J.D., Münzer T., et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA 288 (2002) 2282-2292
9. Bosaeus I., Johansson G., Rosén T., et al. Comparison of methods to estimate body fat in growth hormone deficient adults. Clin. Endocrinol. 44 (1996) 395-402
10. Bray G.A. Medical consequences of obesity. J. Clin. Endocrinol. Metab. (2004) 2583-2589
11. Brill K.T., Weltman A.L., Gentili A., et al. Single and combined effects of growth hormone and testosterone administration on measures of body composition, physical performance, mood, sexual function, bone turnover, and muscle gene expression in healthy older men. J. Clin. Endocrinol. Metab. 87 (2002) 5649-5657
12. Brochu M., Starling R.D., Tcernof A., Matthews D.E., Garcia-Rubi E., et al. Visceral adipose tissue is an independent correlate of glucose disposal in older obese postmenopausal women. J. Clin. Endocrinol. Metab. 85 (2000) 2378-2384
13. Busetto L. Visceral obesity and the metabolic syndrome: effects of weight loss. Nutr. Metab. Cardiovasc. Dis. 11 (2001) 195-204
14. Chrisolidou A., Beshyah S., Rutherford O., et al. Effects of seven years of growth hormone replacement therapy in hypopituitary adults. J. Clin. Endocrinol. Metab. 85 (2000) 3762-3769
15. Clasey J.L., Weltman A., Patrie J., et al. Abdominal visceral fat and fasting insulin are important predictors of 24-hour GH release Independent of age, gender, and other physiological factors. J. Clin. Endocrinol. Metab. 86 (2001) 3845-3852
16. Clemmons D.R., Snyder D.K., Williams R., and Underwood L.E. Growth hormone administration conserves lean body mass during dietary restriction in obese subjects. J. Clin. Endocrinol. Metab. 64 (1987) 878-883
17. Cordido F., Penalva A., Diequez C., and Casanueva F.F. Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capacity in obesity. J. Clin. Endocrinol. Metab. 76 (1993) 819-823
18. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society workshop on adult growth hormone deficiency. J. Clin. Endocrinol. Metab. 1998; 83: 379-381.
19. Cummings D.E., and Merriam G.R. Growth hormone therapy in adults. Annu. Rev. Med. 54 (2003) 513-533
20. De Marinis L., Bianchi A., Mancini A., et al. Growth hormone secretion and leptin in morbid obesity before and after biliopancreatic diversion: realtionships with insulin and body composition. J. Clin. Endocrinol. Metab. 89 (2004) 174-180
21. De Pergola G., Zamboni G.M., Pannacciulli N., et al. Divergent effects of short-term, very-low-calorie diet on insulin-like growth factor-I and insulin-like growth factor binding protein-3 serum concentrations in premenopausal women with obesity. Obes. Res. 6 (1998) 408-415
22. Després J.P., Lemieux I., and Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ 322 (2001) 716-720
23. Despres J.P. Is visceral obesity the cause of the metabolic syndrome?. Ann. Med. 38 (2006) 52-63
24. Drent M.L., Wever L.D., Ader H.J., and van der Veen E.A. Growth hormone administration in addition to a very low calorie diet and an exercise program in obese subjects. Eur. J. Endocrinol. 132 (1995) 565-572
25. Eliman A., Norgren S., and Marcus C. Effects of growth hormone treatment on the leptin stem and body composition in obese prepubertal boys. Acta Paedr. 90 (2001) 520-525
26. Engström B.E., Burman P., Holdstock C., Öhrval M., Sundbom M., and Karlsson F.A. Effects of gastric bypass on the GH/IGF-I axis in severe obesity-and a comparison with GH deficiency. Eur. J. Endocrinol. 154 (2006) 53-59
27. Fisker S. Physiology and pathophysiology of growth hormone-binding protein: methodological and clinical aspects. Growth Horm. IGF Res. (2006) 161-228
28. Franco C., Brandberg J., Lonn L., Andersson B., Bengtsson B.A., and Johannsson G. Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: a 12-month placebo-controlled trial. J. Clin. Endocrinol. Metab. 90 (2005) 1466-1474
29. Frystyk J., Vestbo E., Skjærbæk C., Mogensen C.E., and Ørskov H. Free Insulin-like growth factors in human obesity. Metabolism 44 Suppl 4 (1995) 37-44
30. Frystyk J., Skjaerbaek C., Vestbo E., Fisker A., and Ørskov H. Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes. Diabetes Metab. Res. Rev. 15 (1999) 314-322
31. Frystyk J. Free insulin-like growth factors-measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Horm. IGF Res. 14 (2004) 337-375
32. Giannoulis M.G., Sonksen P.H., Umpleby M., et al. The effects of growth hormone and/or testosterone in healthy elderly men; a randomized controlled trial. J. Clin. Endocrinol. Metab. 91 (2006) 477-484
33. Gibney J., Wallace J.D., Spinks T., et al. The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients. J. Clin. Endocrinol. Metab. 84 (1999) 2596-2602
34. Gomez J.M., Maravall F.J., Gomez N., Navarro M.A., Casamitjana R., and Soler J. The IGF-I system component concentrations that decrease with ageing are lower in obesity in relationship to body mass index and body fat. Growth Horm. IGF Res. 14 (2004) 91-96
35. Godenberg N., and Barkan A. Factor's regulating growth hormone secretion in humans. Endocrinol. Metab. Clin. N. Am. 36 (2007) 37-55
36. Grottoli S., Gauna C., Tassone F., et al. Both fasting-induced leptin reduction and GH increase are blunted in Cushing's syndrome and in simple obesity. Clin. Endocrinol. 58 (2003) 220-228
37. Halpern A., mancini M.C., Cercato C., Vilares S.M., and Costa A.P. Effects of growth hormone on anthropometric and metabolic parameters in android obesity. Arquivos Brasileiros de Endocrinologia e Metabologia 50 (2006) 68-73
38. Hartman M.L., Veldhuis J.D., Johnsson M.L., lee M.M., Alberti K.G., Samojlik E., and Thorner M.O. Augumented growth hormone (GH) secretory burst frequency and amplitude mediate GH secretion during a two-day fast in normal men. J. Clin. Endocrinol. Metab. 74 (1992) 757-765
39. Heffernan M.A., Thornburn A.W., Fam B., et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int. J. Obes. Relat. Metab. Disord. 25 (2001) 1442-1449
40. Herd C., Wittert G., Caterson I., et al. The effect of AOD9604 on weight loss in obese adults: results of a randomized, double-blind, placebo-controlled, multicenter study. Annual Scientific Meeting of the North American Association for the Study of Obesity, October 18, 2005. Vancouver, British Columbia, Canada (2005)
41. Hochberg Z., Hertz P., Colin V., et al. The distal axis of growth hormone (GH) in nutritional disorders: GH-binding protein, insulin-like growth factor-I (IGF-I) and IGF receptors in obesity and anorexia nervosa. Metabolism 41 (1992) 106-112
42. Iranmanesh A., Lizarralde G., and Veldhuis. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. J. Clin. Endocrinol. Metab. 73 (1991) 1081-1088
43. Johannsson G., Marin P., Lonn L., et al. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J. Clin. Endocrinol. Metab. 82 (1997) 727-734
44. Johnsen S.P., Hundborg H.H., Sørensen H.T., et al. Insulin-like growth factor (IGF) I, -II, and IGF binding protein-3 and risk of ischemic stroke. J. Clin. Endocrinol. Metab. 90 (2005) 5937-5941
45. Jones J.I., and Clemmons D.R. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 16 (1995) 3-34
46. Juul A., Scheike T., Davidsen M., Gyllenborg J., and Jørgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease. Circulation 106 (2002) 939-944
47. Juul A. Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm. IGF Res. 13 (2003) 113-170
48. Jørgensen J.O.L., Pedersen S.A., Thuesen L., et al. Beneficial effect of growth hormone treatment in GH-deficient adults. Lancet 333 (1989) 1221-1225
49. Jørgensen J.O., Pedersen S.B., Børglum J., et al. Fuel metabolism, energy expenditure, and thyroid function in growth hormone-treated obese women: a double-blind placebo-controlled study. Metabolism 43 (1994) 872-877
50. Jørgensen J.O.L., Møller L., Krag, Billestrup N., and Christiansen J.S. Effects of growth hormone on glucose and fat metabolism in human subjects. Endocrinol. Metab. Clin. N. Am. 36 (2007) 75-87
51. Kamel A., Norgren S., Elimam A., Danielsson P., and Marcus C. Effects of growth hormone treatment in obese prepubertal boys. J. Clin. Endocrinol. Metab. 85 (2000) 1412-1419
52. Kershaw E.E., and Flier J.S. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 89 (2004) 2548-2556
53. Kim K.R., Nam S.Y., Song Y.D., et al. Low-dose growth hormone treatment with diet restriction accelerates body fat loss, exerts anabolic effect and improves growth hormone secretory dysfunction in obese adults. Horm. Res. 51 (1999) 78-84
54. Kunitomi M., Wada J., Takahasi K., et al. Relationship between reduced serum IGF-I levels and accumulation of visceral fat in Japanese men. Int. J. Obes. 26 (2002) 361-369
55. Langendonk J.G., Meinders A.E., Burggraaf J., et al. Influence of obesity and body fat distribution on growth hormone kinetics in humans. Am. J. Physiol. 277 (1999) E824-E829
56. Leung D.W., Spencer S.A., Cachoianes G., et al. Growth hormone receptor and serum binding protein: purification, cloning and expression. Nature 330 (1987) 537-543
57. Makimura H., Stanley T., Mun D., You S.M., and Grinspoon S. The effects of central adiposity on growth hormone (GH) response to GH-releasing hormone-arginine stimulation testing in men. J. Clin. Endocrinol. Metab. 93 (2008) 4254-4260
58. The Endocrine Society's Clinical Guidelines Subcommittee. Evaluation and treatment of adult growth hormone deficiency: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 91 (2006) 1621-1634
59. Münzer T., Harman S.M., Hees P., et al. Effects of GH and/or sex steroid administration on abdominal subcutaneous and visceral fat in healthy aged women and men. J. Clin. Endocrinol. Metab. 86 (2001) 3604-3610
60. Møller N., Copeland K.C., and Nair K.S. Growth hormone effects on protein metabolism. Endocrinol. Metab. Clin. N. Am. 36 (2007) 89-100
61. Mårin P., Kvist H., Lindstedt G., Sjöström L., and Björntorp P. Low concentrations of insulin-like growth factor-I in abdominal obesity. Int. J. Obes. 17 (1993) 83-89
62. Nam S.Y., Lee E.J., Kim K.R., et al. Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone. Int. J. Obes. 21 (1997) 355-359
63. Nam S.Y., Kim K.R., Cha B.S., et al. Low-dose growth hormone treatment combined with diet restriction decreases insulin resistance by reducing visceral fat and increasing muscle mass in obese type 2 diabetic patients. Int. J. Obes. 25 (2001) 1101-1107
64. Nyomba B.L.G., Johnson M., Berard L., and Murphy L.J. Relationship between serum leptin and the insulin-like growth factor-I system in humans. Metabolism 48 (1999) 840-844
65. Nørrelund H., Borglum J., Jorgensen J.O., et al. Effects of growth hormone administration on protein dynamics and substrate metabolism during 4 weeks of dietary restriction in obese women. Clin. Endocrinol. 52 (2000) 305-312
66. Peiris A.N., Sothman M.S., Hoffmann R.G., et al. Adiposity, fat distribution and cardiovascular risk. Ann. Intern. Med. 110 (1989) 867-872
67. Pasarica M., Zachwieja J.J., DeJonge L., Redman S., and Smith S.R. Effect of growth hormone on body composition and visceral adiposity in middle-aged men with visceral obesity. J. Clin. Endocrinol. Metab. 92 (2007) 4265-4270
68. Raben M., and Hollenberg C. Effects of growth hormone on plasma fatty acids. J. Clin. Invest. 38 (1959) 484-488
69. Rasmussen M.H., Frystyk J., Andersen T., Breum L., Christiansen J.S., and Hilsted J. The impact of obesity, fat distribution and energy restriction on insulin-like growth factor-1 (IGF-1), IGF-binding protein-3 and growth hormone. Metabolism 43 (1994) 315-319
70. Rasmussen M.H., Juul A., Kjems L.L., Skakkebæk N.E., and Hilsted J. Lack of stimulation of 24-hour growth hormone release by hypocaloric diet in obesity. J. Clin. Endocrinol. Metab. 80 (1995) 796-801
71. Rasmussen M.H., Hvidberg A., Juul A., Main K.M., Gotfredsen A., Skakkebæk N.E., and Hilsted J. Massive Weight loss restores 24-hour growth hormone release profiles and serum insulin-like growth factor-I levels in obese subjects. J. Clin. Endocrinol. Metab. 80 (1995) 1407-1415
72. Rasmussen M.H., Ho K.Y.Y., Kjems L.L., and Hilsted J. Serum growth hormone binding protein in obesity: effect of short term very low calorie diet and diet induced weight loss. J. Clin. Endocrinol. Metab. 81 (1996) 1519-1524
73. Rasmussen M.H., Juul A., Kjems L.L., and Hilsted J. Effects of short-term caloric restriction on circulating free insulin-like growth factor (IGF)-I, acid-labile subunit, IGF- binding protein (IGFBP)-1, -2, -3, -4, and IGFBP-1, -2, -3, protease activity in obese subjects. Eur J Endocrinol 155 (2006) 575-581
74. Rasmussen M.H., Juul A., Hilsted J. Effect of weight loss on free insulin-like growth factor-I in obese women with hyposomatotropism. 2007;15:879-886.
75. Rasmussen M.H., Wildschiødtz G., Juul A., and Hilsted J. Polysomnographic sleep, growth hormone-insulin-like growth factor-I axis, leptin and weight loss. Obesity 16 (2008) 1516-1521
76. Ricart W., and Fernandez-Real J.M. No decrease in free IGF-I with increasing insulin in obesity-related insulin resistance. Obes. Res. 9 (2001) 631-636
77. Richelsen B., Pedersen S.B., Borglum J.D., Moller-Pedersen T., Jorgensen J., and Jorgensen J.O. Growth hormone treatment of obese women for 5 wk: effect on body composition and adipose tissue LPL activity. Am. J. Physiol. 266 (1994) E211-E216
78. Richelsen B., Pedersen S.B., Kristensen K., et al. Regulation of lipoprotein lipase and hormone-sensitive lipase activity and gene expression in adipose and muscle tissue by growth hormone treatment during weight loss in obese patients. Metab. Clin. Exp. 49 (2000) 906-911
79. Rosenfeld R.G. Growth hormone deficiency in children. In: Degroot L.J., and Jameson J.L. (Eds). Endocrinology. 4th ed. (2001), W.B. Saunders 503-519
80. Satorio S., Malffiuletti N.A., Agosti F., et al. Body mass reduction markedly improves muscle performance and body composition in obese females aged 61-75 years: comparison between the effects exerted by energy-restricted diet plus moderate aerobic-strength training alone or associated with rGH or nandrolone. Eur. J. Endocrinol. 150 (2004) 511-515
81. Salomon F., Cuneo R., Hesp R., and Sönksen P. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N. Engl. J. Med. 321 (1989) 1221-1225
82. Sandhu M.S., Heald A.H., Gibson J.M., Cruickshank J.K., Dunger D.B., and Warreham N.J. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet 359 (2002) 1740-1745
83. Shadid S., and Jensen M.D. Effects of growth hormone administration in human obesity. Obes. Res. 11 (2003) 170-175
84. * GRS Council. Growth hormone replacement therapy for adults: into the new millennium. Growth Horm. IGF Res. 12 (2002) 1-33
85. Skaggs S.R., and Crist D.M. Exogenous human growth hormone reduces body fat in obese women. Horm. Res. 35 (1991) 19-24
86. Smith S.R., and Zachwieja J.J. Visceral adipose tissue: a critical review of intervention strategies. Int. J. Obes. Relat. Metab. Disord. 23 (1999) 329-335
87. Snyder D.K., Clemmons D.R., and Underwood L.E. Treatment of obese, diet-restricted subjects with growth hormone for 11 weeks: effects on anabolism, lipolysis, and body composition. J. Clin. Endocrinol. Metab. 67 (1988) 54-61
88. Snyder D.K., Clemmons D.R., and Underwood L.E. Dietary carbohydrate content determines responsiveness to growth hormone in energy-restricted humans. J. Clin. Endocrinol. Metab. 69 (1989) 745-752
89. Snyder D.K., Underwood L.E., and Clemmons D.R. Anabolic effects of growth hormone in obese diet-restricted subjects are dose dependent. Am. J. Clin. Nutr. 52 (1990) 431-437
90. Snyder D.K., Underwood L.E., and Clemmons D.R. Persistent lipolytic effect of exogenous growth hormone during caloric restriction. Am. J. Med. 98 (1995) 129-134
91. Street M.E., Ziveri M.A., Spaggiari C., et al. Inflammation is a modulator of the insulin-like growth factor (IGF)/IGF-binding protein system inducing reduced bioactivity of IGFs in cystic fibrosis. Eur. J. Endocrinol. 154 (2006) 47-52
92. Taaffe D.R., Pruitt L., Reim J., et al. Effect of recombinant human growth hormone on the muscle strength response to resistance exercise in elderly men. J. Clin. Endocrinol. Metab. 79 (1994) 1361-1366
93. Taaffe D.R., Thompson J.L., Butterfield G.E., Hoffman A.R., and Marcus R. Recombinant human growth hormone, but not insulin-like growth factor-I enhances central fat loss in postmenopausal women undergoing a diet and exercise program. Horm. Metab. Res. 33 (2001) 156-162
94. Tagliaferri M., Scacchi M., Pincelli A.I., et al. Metabolic effects of biosynthetic growth hormone treatment in severely energy-restricted obese women. Int. J. Obes. 22 (1998) 836-841
95. Tankó L.B., Bruun J.M., Alexandersen P., Bagger Y.Z., Richelsen B., Christiansen C., and Larsen P.J. Novel associations between bioavailable estradiol and adipokines in elderly women with different phenotypes of obesity: implications for atherogenesis. Circulation 110 (2004) 2246-2252
96. Thompson J.L., Butterfield G.E., Gylfadöttir U.K., et al. Effects of human growth hormone, insulin-like growth factor I, and diet and exercise on body composition of obese postmenopausal women. J. Clin. Endocrinol. Metab. 83 (1998) 1477-1484
97. Utz A.L., Yamamoto A., Hemphill L., and Miller K.K. Growth hormone deficiency by growth hormone releasing hormone-arginine testing criteria predicts increased cardiovascular risk markers in normal young overweight and obese women. J. Clin. Endocrinol. Metab. 93 (2008) 2507-25149
98. Vance M.L., and Mauras N. Growth hormone therapy in adults and children. N. Eng. J. Med. 341 (1999) 1206-1214
99. Veldhuis J.D., Iranmanesh A., Ho K.K., Waters M.J., Johnson M.I., and Lizzarralde G. Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man. J. Clin. Endocrinol. Metab. 72 (1991) 51-59
100. Weaver J.U., Monson J.P., Noonan K., et al. The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity and cardiovascular risk factors in hypopituitary adults. J. Clin. Endocrinol. Metab. 80 (1995) 153-159
101. Whitehead H., Boreman C., Mcllrath E., et al. Growth hormone treatment of adults with growth hormone deficiency: results of a 13-month placebo-controlled cross-over study. Clin. Endocrinol. 36 (1992) 45-52
102. Yuen K., Ong K., Husbands S., Chatelain P., Fryklund L., Gluckman P., Ranke M., Cook D., Rosenfeld R., Wass J., and Dunger D. The effects of short-term administration of two low doses versus the standard GH replacement dose on insulin sensitivity and fasting glucose levels in young healthy adults. J. Clin. Endocrinol. Metab. 87 (2002) 1989-1995